News
ENSC
0.5690
-6.41%
-0.0390
Weekly Report: what happened at ENSC last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at ENSC last week (0415-0419)?
Weekly Report · 04/22 11:02
Weekly Report: what happened at ENSC last week (0408-0412)?
Weekly Report · 04/15 10:55
Weekly Report: what happened at ENSC last week (0401-0405)?
Weekly Report · 04/08 10:59
Weekly Report: what happened at ENSC last week (0325-0329)?
Weekly Report · 04/01 10:57
Weekly Report: what happened at ENSC last week (0318-0322)?
Weekly Report · 03/25 10:59
Ensysce Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Ensysce Biosciences Inc reports results for the quarter ended in December. Revenue fell 64.1% to $515.03 thousand from a year ago. The company reported a quarterly adjusted loss of $1.37 per share. The mean expectation of three analysts was for a loss of 87 cents.
Reuters · 03/19 21:01
Ensysce Biosciences Inc <ENSC.OQ> expected to post a loss of 93 cents a share - Earnings Preview
Ensysce Biosciences Inc expected to post a loss of 93 cents a share. The company is expected to report a 49.4% decrease in quarterly revenue to $400 thousand from $790 thousand a year ago. The one available analyst rating on the shares is 'buy'
Reuters · 03/19 12:42
FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today
Fisker (NYSE:FSR) stock is moving on Monday after the electric vehicle (EV) company announced that it has secured an additional $150 million in funding. Shares of Fisker stock are down 12% this morning. The company is still in talks with a large automaker to develop an EV platform. FSR stock has 136 million shares changing hands.
Investorplace · 03/18 15:13
ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023
Ensysce Biosciences reported results for the fourth quarter of 2023. The company reported earnings per share of -$1.13 and revenue of $515,032. This was below the analyst estimate for EPS of -87 cents. Ensysce reported revenue was 32.06% better than expected.
Investorplace · 03/18 14:53
Weekly Report: what happened at ENSC last week (0311-0315)?
Weekly Report · 03/18 10:58
Ensysce Biosciences Inc <ENSC.OQ> expected to post a loss of 93 cents a share - Earnings Preview
Ensysce Biosciences Inc expected to post a loss of 93 cents a share. The company is expected to report a 68.4% decrease in quarterly revenue to $250 thousand from $790 thousand a year ago. The one available analyst rating on the shares is 'buy'
Reuters · 03/15 20:40
Ensysce Biosciences reports Q4 results
Seeking Alpha · 03/15 14:26
Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Ensysce Biosciences reported quarterly losses of $1.13 per share. The company missed the analyst consensus estimate of $0.87 per share for the same period last year. Ensysce also reported quarterly sales of $515.03 thousand which beat the estimate by 32.06 percent.
Benzinga · 03/15 12:06
Weekly Report: what happened at ENSC last week (0304-0308)?
Weekly Report · 03/11 10:56
Weekly Report: what happened at ENSC last week (0226-0301)?
Weekly Report · 03/04 10:58
Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
Ensysce Biosciences, Inc. Is a clinical-stage company applying transformative chemistry to improve prescription drug safety. Nasdaq has extended the Company's listing on The Nasdaq Stock Market to May 13, 2024. The Company may continue its listing on the Nasdaq Capital Market tier.
Benzinga · 02/27 13:11
Weekly Report: what happened at ENSC last week (0219-0223)?
Weekly Report · 02/26 11:09
Ensysce Biosciences Receives FDA Guidance For PF614-MPAR Program
FDA meeting focused on the Company's non-clinical program for the treatment of severe pain. The FDA provided helpful feedback and advice on non- clinical studies required for eventual NDA submission and approval. PF614-MPAR is a combination drug designed for treatment of pain.
Benzinga · 02/21 13:06
Weekly Report: what happened at ENSC last week (0212-0216)?
Weekly Report · 02/19 11:11
More
Webull provides a variety of real-time ENSC stock news. You can receive the latest news about Ensysce Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.